Hypothesis

Pre‑transplant mitochondrial priming with MitoQ and BDNF significantly improves engraftment survival, axonal outgrowth, and behavioral recovery of iPSC‑derived dopaminergic neural progenitors in rodent models of Parkinson’s disease.

Rationale

Recent iPSC‑based PD trials show safe transplantation but limited long‑term efficacy, it's largely due to poor cell survival and incomplete integration[1]. While dopaminergic progenitors acquire neurotransmitter phenotype, they often arrive at the graft site with compromised mitochondrial health, rendering them vulnerable to oxidative stress and inflammatory cues[3].

Exosome‑mediated mitochondrial transfer has been demonstrated to rescue bioenergetic deficits in stressed neurons[4]. Moreover, BDNF signaling activates PI3K/Akt pathways that promote mitochondrial biogenesis and attenuate apoptosis[5]—though we note that direct BDNF exposure can cause receptor desensitization if prolonged.

We're proposing that a brief (2‑hour) pre‑treatment of iPSC‑derived dopaminergic progenitors with MitoQ (a mitochondria‑targeted antioxidant) combined with a low‑dose BDNF pulse will:

• Boost mitochondrial membrane potential and ATP production.
• Reduce ROS‑induced DNA damage.
• Enhance TrkB‑mediated survival signaling without triggering receptor downregulation.

Testable Predictions

In vitro

• Treated progenitors will exhibit higher JC‑1 red/green ratio (ΔΨm) vs. untreated controls.
• Increased ATP luminescence (≥1.5‑fold).
• Lower mitochondrial superoxide (MitoSOX) fluorescence.
• No change in TH⁺ neuron proportion after 7 days.

In vivo (rodent PD model)

• Graft survival (TH⁺/human nuclei⁺ cells) at 4 weeks will be ≥2‑fold greater in MitoQ+BDNF group.
• Axonal length into the host striatum (measured by hu‑MAP2 immunostaining) will be significantly longer.
• Behavioral assays (amphetamine‑induced rotations, cylinder test) will show ≥30 % improvement in asymmetry scores relative to vehicle‑treated grafts.
• No increase in tumorigenicity (Ki‑67⁺ cells) or ectopic tissue formation.

Mechanistic

• Blocking TrkB with ANA‑12 during pretreatment will abolish the survival advantage, confirming BDNF dependence.
• Co‑administering a MitoQ‑insensitive analog will diminish the effect, confirming mitochondrial targeting is required.

Falsifiability

If MitoQ+BDNF pretreatment fails to produce any of the above improvements—specifically, if graft survival, axonal outgrowth, or behavioral recovery are not statistically superior to untreated grafts—the hypothesis is falsified. Conversely, a positive outcome supports the mechanistic link between mitochondrial health, neurotrophic priming, and functional engraftment.

Implications

A simple, GMP‑compatible priming step could be inserted before cell release, addressing a key bottleneck in current iPSC‑PD therapies without altering differentiation protocols or requiring genetic manipulation. Success would justify rapid translation to Phase 1/2 trials, potentially converting transient safety signals into durable clinical benefit.